Athera Biotechnologies And Dyax Announce A Collaboration To Discover And Develop Antibodies For Cardiovascular Inflammation

Athera Biotechnologies AB and Dyax Corp. (NASDAQ:DYAX) announced that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases. The collaboration follows the recent publication of work by Athera scientific founders, Professors Frostegard and de Faire of the Karolinska Institutet.

More: continued here

Filed under: Cardiovascular on October 3rd, 2008